Scarica l'app Stockscreener
6.14
8.22%
-0.55
Dopo l'orario di chiusura:
6.14
Precedente Chiudi:
$6.69
Aprire:
$6.61
Volume 24 ore:
105.03K
Relative Volume:
0.99
Capitalizzazione di mercato:
$150.52M
Reddito:
-
Utile/perdita netta:
$-22.38M
Rapporto P/E:
-4.3546
EPS:
-1.41
Flusso di cassa netto:
$-15.54M
1 W Prestazione:
-16.58%
1M Prestazione:
-9.71%
6M Prestazione:
-9.71%
1 anno Prestazione:
-42.62%
Intervallo 1D:
$6.0901
$6.75
Intervallo di 1 settimana:
$6.0901
$7.3604
Portata 52W:
$4.44
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Confronta NVCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.14 | 150.52M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Q1 EPS Estimates for Nuvectis Pharma Reduced by Roth Capital - Defense World
HC Wainwright Weighs in on Nuvectis Pharma Q1 Earnings - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Nuvectis Pharma (NVCT) to Release Earnings on Tuesday - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Price Target Lowered to $11.00 at HC Wainwright - MarketBeat
FY2028 EPS Forecast for Nuvectis Pharma Reduced by Analyst - MarketBeat
FY2028 EPS Estimates for Nuvectis Pharma Reduced by Analyst - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Progress - TipRanks
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets - Marketscreener.com
HC Wainwright Lowers Nuvectis Pharma (NASDAQ:NVCT) Price Target to $11.00 - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Updates on Oncology Pipeline - Defense World
Nuvectis Pharma initiated with a Buy at Lucid Capital - TipRanks
Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position - TipRanks
Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright - TipRanks
Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year - TipRanks
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights - The Manila Times
How Nuvectis Pharma Cut Losses by $3.3M While Pushing Forward Two Cancer Drug Candidates - StockTitan
Insiders Rewarded With US$915k Addition To Investment As Nuvectis Pharma Stock Hits US$185m - Simply Wall St
Nuvectis Pharma announces pricing of $13.5M public offering - MSN
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases $1,200,000.00 in Stock - MarketBeat
Nuvectis pharma investor acquires $1.2 million in stock - MSN
(NVCT) Investment Analysis and Advice - Stock Traders Daily
Nuvectis Pharma Insider Bought Shares Worth $1,200,000, According to a Recent SEC Filing - Marketscreener.com
Major Investment Alert: Shareholder’s Big Move in Nuvectis Pharma! - TipRanks
Nuvectis pharma investor acquires $1.2 million in stock By Investing.com - Investing.com
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis Pharma Closes Stock Offering, Says Underwriter Exercised Overallotment Option - Marketscreener.com
Nuvectis Pharma Announces Closing of $15.5 Million Public - GlobeNewswire
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option - Yahoo Finance
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback - Seeking Alpha
Nuvectis Pharma launches public stock offering - MSN
Nuvectis Pharma 2.7M share Spot Secondary priced at $5.00 - MSN
Nuvectis Pharma Prices $13.5 Million Public Offering of Shares -February 05, 2025 at 10:52 am EST - Marketscreener.com
Nuvectis Pharma Prices of $13.5 Million Public Offering of Common Stock - citybiz
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock - GlobeNewswire
Nuvectis pharma announces proposed public offering of common stock - MSN
Nuvectis Secures Critical $13.5M Funding: Major Push for Revolutionary Cancer Drug Development - StockTitan
Nuvectis Pharma launches public stock offering By Investing.com - Investing.com Australia
Nuvectis Pharma Announces Proposed Public Offering of Common Stock - GlobeNewswire
Nuvectis Pharma's Strategic Funding Move: Key Details on Oncology Pipeline Investment - StockTitan
(NVCT) Trading Signals - Stock Traders Daily
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Bought by Baldwin Wealth Partners LLC MA - MarketBeat
How To Trade (NVCT) - Stock Traders Daily
Geode Capital Management LLC Has $501,000 Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Proactive Strategies - Stock Traders Daily
Nuvectis Pharma: Still Flat, Although There May Be A Ground Floor Here - Seeking Alpha
Insiders hold 63% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently - Yahoo Finance
(NVCT) Long Term Investment Analysis - Stock Traders Daily
Great week for Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who have 63% stake and they haven’t stopped buying - Simply Wall St
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvectis Pharma Inc Azioni (NVCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
| BENTSUR RON | Chairman & CEO |
Nov 15 '24 |
Buy |
4.92 |
20,000 |
98,400 |
3,266,424 |
| Carson Michael J. | Vice President, Finance |
Nov 07 '24 |
Sale |
8.16 |
2,755 |
22,478 |
87,918 |
| BENTSUR RON | Chairman & CEO |
May 14 '24 |
Buy |
6.74 |
1,940 |
13,076 |
3,246,424 |
| BENTSUR RON | Chairman & CEO |
May 10 '24 |
Buy |
6.40 |
2,000 |
12,800 |
3,244,484 |
| Poradosu Enrique | Chief Science & Business Off |
May 10 '24 |
Buy |
6.29 |
500 |
3,145 |
1,504,319 |
| Shemesh Shay | Chief Dev. & Ops. Officer |
May 10 '24 |
Buy |
6.32 |
1,113 |
7,034 |
1,493,068 |
| BENTSUR RON | Chairman & CEO |
Mar 18 '24 |
Buy |
10.29 |
5,000 |
51,450 |
3,242,484 |
6.45%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):